A Novel Blood Proteomic Signature for Prostate Cancer
Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined wi...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-02, Vol.15 (4), p.1051 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 1051 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Muazzam, Ammara Spick, Matt Cexus, Olivier N F Geary, Bethany Azhar, Fowz Pandha, Hardev Michael, Agnieszka Reed, Rachel Lennon, Sarah Gethings, Lee A Plumb, Robert S Whetton, Anthony D Geifman, Nophar Townsend, Paul A |
| description | Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484. |
| doi_str_mv | 10.3390/cancers15041051 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9954127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743010031</galeid><sourcerecordid>A743010031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-8e067350053ff3d36983930108e595f1ae2d876bc0cd4116a30ae72c51aff2233</originalsourceid><addsrcrecordid>eNptUt1LHDEQD6VSRX3uW1noS_twOslsNtmXwnlULRxaaPscYnZyruxtbLJ70P--We8qejR5yDD5fSQzw9h7DmeINZw72zuKiUsoOUj-hh0JUGJWVXX59kV8yE5TeoC8ELmq1Dt2iJVGjjUeMTkvbsKGuuKiC6EpvscwUFi3rvjRrno7jJEKH-KUT4MdqFg8eZ6wA2-7RKe785j9uvz6c3E9W95efVvMlzMnhRhmmqBSKAEkeo8NVrXOpsBBk6yl55ZEo1V158A1JeeVRbCkhJPcei8E4jH7stV9HO_W1Djqh2g78xjbtY1_TLCteX3Tt_dmFTamrmXJhcoCn7cC93u06_nSTDkoQWot9YZn7KedWQy_R0qDWbfJUdfZnsKYjFAaQHEsqwz9uAd9CGPscykyStUSuXgy36FWtiPT9j7kN7pJ1MxVOdUBcLI9-w8q74ZyH0JPvs35V4TzLcHlpqRI_vljHMw0GGZvMDLjw8syPuP_jQH-BXC-sDQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2779531227</pqid></control><display><type>article</type><title>A Novel Blood Proteomic Signature for Prostate Cancer</title><source>PMC (PubMed Central)</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Muazzam, Ammara ; Spick, Matt ; Cexus, Olivier N F ; Geary, Bethany ; Azhar, Fowz ; Pandha, Hardev ; Michael, Agnieszka ; Reed, Rachel ; Lennon, Sarah ; Gethings, Lee A ; Plumb, Robert S ; Whetton, Anthony D ; Geifman, Nophar ; Townsend, Paul A</creator><creatorcontrib>Muazzam, Ammara ; Spick, Matt ; Cexus, Olivier N F ; Geary, Bethany ; Azhar, Fowz ; Pandha, Hardev ; Michael, Agnieszka ; Reed, Rachel ; Lennon, Sarah ; Gethings, Lee A ; Plumb, Robert S ; Whetton, Anthony D ; Geifman, Nophar ; Townsend, Paul A</creatorcontrib><description>Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15041051</identifier><identifier>PMID: 36831393</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acids ; Age ; Antigens ; Apolipoproteins ; Biomarkers ; Biopsy ; Blood ; Cancer therapies ; Clotting ; Diagnosis ; Health aspects ; Life Sciences ; Mass spectrometry ; Mass spectroscopy ; Medical examination ; Medicare ; Older people ; Patients ; Peptides ; Peripheral blood ; Prostate cancer ; Prostate-specific antigen ; Proteins ; Proteomics ; Radiation therapy ; Scientific imaging ; Surveillance ; Tumors ; Urogenital system</subject><ispartof>Cancers, 2023-02, Vol.15 (4), p.1051</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-8e067350053ff3d36983930108e595f1ae2d876bc0cd4116a30ae72c51aff2233</citedby><cites>FETCH-LOGICAL-c522t-8e067350053ff3d36983930108e595f1ae2d876bc0cd4116a30ae72c51aff2233</cites><orcidid>0000-0001-5095-0141 ; 0000-0002-9417-6511 ; 0000-0002-7262-6227 ; 0000-0001-8956-9508 ; 0000-0003-2956-6676 ; 0000-0003-3773-3323</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954127/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954127/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36831393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04058858$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Muazzam, Ammara</creatorcontrib><creatorcontrib>Spick, Matt</creatorcontrib><creatorcontrib>Cexus, Olivier N F</creatorcontrib><creatorcontrib>Geary, Bethany</creatorcontrib><creatorcontrib>Azhar, Fowz</creatorcontrib><creatorcontrib>Pandha, Hardev</creatorcontrib><creatorcontrib>Michael, Agnieszka</creatorcontrib><creatorcontrib>Reed, Rachel</creatorcontrib><creatorcontrib>Lennon, Sarah</creatorcontrib><creatorcontrib>Gethings, Lee A</creatorcontrib><creatorcontrib>Plumb, Robert S</creatorcontrib><creatorcontrib>Whetton, Anthony D</creatorcontrib><creatorcontrib>Geifman, Nophar</creatorcontrib><creatorcontrib>Townsend, Paul A</creatorcontrib><title>A Novel Blood Proteomic Signature for Prostate Cancer</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.</description><subject>Acids</subject><subject>Age</subject><subject>Antigens</subject><subject>Apolipoproteins</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Blood</subject><subject>Cancer therapies</subject><subject>Clotting</subject><subject>Diagnosis</subject><subject>Health aspects</subject><subject>Life Sciences</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Medical examination</subject><subject>Medicare</subject><subject>Older people</subject><subject>Patients</subject><subject>Peptides</subject><subject>Peripheral blood</subject><subject>Prostate cancer</subject><subject>Prostate-specific antigen</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Radiation therapy</subject><subject>Scientific imaging</subject><subject>Surveillance</subject><subject>Tumors</subject><subject>Urogenital system</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptUt1LHDEQD6VSRX3uW1noS_twOslsNtmXwnlULRxaaPscYnZyruxtbLJ70P--We8qejR5yDD5fSQzw9h7DmeINZw72zuKiUsoOUj-hh0JUGJWVXX59kV8yE5TeoC8ELmq1Dt2iJVGjjUeMTkvbsKGuuKiC6EpvscwUFi3rvjRrno7jJEKH-KUT4MdqFg8eZ6wA2-7RKe785j9uvz6c3E9W95efVvMlzMnhRhmmqBSKAEkeo8NVrXOpsBBk6yl55ZEo1V158A1JeeVRbCkhJPcei8E4jH7stV9HO_W1Djqh2g78xjbtY1_TLCteX3Tt_dmFTamrmXJhcoCn7cC93u06_nSTDkoQWot9YZn7KedWQy_R0qDWbfJUdfZnsKYjFAaQHEsqwz9uAd9CGPscykyStUSuXgy36FWtiPT9j7kN7pJ1MxVOdUBcLI9-w8q74ZyH0JPvs35V4TzLcHlpqRI_vljHMw0GGZvMDLjw8syPuP_jQH-BXC-sDQ</recordid><startdate>20230207</startdate><enddate>20230207</enddate><creator>Muazzam, Ammara</creator><creator>Spick, Matt</creator><creator>Cexus, Olivier N F</creator><creator>Geary, Bethany</creator><creator>Azhar, Fowz</creator><creator>Pandha, Hardev</creator><creator>Michael, Agnieszka</creator><creator>Reed, Rachel</creator><creator>Lennon, Sarah</creator><creator>Gethings, Lee A</creator><creator>Plumb, Robert S</creator><creator>Whetton, Anthony D</creator><creator>Geifman, Nophar</creator><creator>Townsend, Paul A</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5095-0141</orcidid><orcidid>https://orcid.org/0000-0002-9417-6511</orcidid><orcidid>https://orcid.org/0000-0002-7262-6227</orcidid><orcidid>https://orcid.org/0000-0001-8956-9508</orcidid><orcidid>https://orcid.org/0000-0003-2956-6676</orcidid><orcidid>https://orcid.org/0000-0003-3773-3323</orcidid></search><sort><creationdate>20230207</creationdate><title>A Novel Blood Proteomic Signature for Prostate Cancer</title><author>Muazzam, Ammara ; Spick, Matt ; Cexus, Olivier N F ; Geary, Bethany ; Azhar, Fowz ; Pandha, Hardev ; Michael, Agnieszka ; Reed, Rachel ; Lennon, Sarah ; Gethings, Lee A ; Plumb, Robert S ; Whetton, Anthony D ; Geifman, Nophar ; Townsend, Paul A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-8e067350053ff3d36983930108e595f1ae2d876bc0cd4116a30ae72c51aff2233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acids</topic><topic>Age</topic><topic>Antigens</topic><topic>Apolipoproteins</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Blood</topic><topic>Cancer therapies</topic><topic>Clotting</topic><topic>Diagnosis</topic><topic>Health aspects</topic><topic>Life Sciences</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Medical examination</topic><topic>Medicare</topic><topic>Older people</topic><topic>Patients</topic><topic>Peptides</topic><topic>Peripheral blood</topic><topic>Prostate cancer</topic><topic>Prostate-specific antigen</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Radiation therapy</topic><topic>Scientific imaging</topic><topic>Surveillance</topic><topic>Tumors</topic><topic>Urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muazzam, Ammara</creatorcontrib><creatorcontrib>Spick, Matt</creatorcontrib><creatorcontrib>Cexus, Olivier N F</creatorcontrib><creatorcontrib>Geary, Bethany</creatorcontrib><creatorcontrib>Azhar, Fowz</creatorcontrib><creatorcontrib>Pandha, Hardev</creatorcontrib><creatorcontrib>Michael, Agnieszka</creatorcontrib><creatorcontrib>Reed, Rachel</creatorcontrib><creatorcontrib>Lennon, Sarah</creatorcontrib><creatorcontrib>Gethings, Lee A</creatorcontrib><creatorcontrib>Plumb, Robert S</creatorcontrib><creatorcontrib>Whetton, Anthony D</creatorcontrib><creatorcontrib>Geifman, Nophar</creatorcontrib><creatorcontrib>Townsend, Paul A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muazzam, Ammara</au><au>Spick, Matt</au><au>Cexus, Olivier N F</au><au>Geary, Bethany</au><au>Azhar, Fowz</au><au>Pandha, Hardev</au><au>Michael, Agnieszka</au><au>Reed, Rachel</au><au>Lennon, Sarah</au><au>Gethings, Lee A</au><au>Plumb, Robert S</au><au>Whetton, Anthony D</au><au>Geifman, Nophar</au><au>Townsend, Paul A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Blood Proteomic Signature for Prostate Cancer</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-02-07</date><risdate>2023</risdate><volume>15</volume><issue>4</issue><spage>1051</spage><pages>1051-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36831393</pmid><doi>10.3390/cancers15041051</doi><orcidid>https://orcid.org/0000-0001-5095-0141</orcidid><orcidid>https://orcid.org/0000-0002-9417-6511</orcidid><orcidid>https://orcid.org/0000-0002-7262-6227</orcidid><orcidid>https://orcid.org/0000-0001-8956-9508</orcidid><orcidid>https://orcid.org/0000-0003-2956-6676</orcidid><orcidid>https://orcid.org/0000-0003-3773-3323</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-02, Vol.15 (4), p.1051 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9954127 |
| source | PMC (PubMed Central); PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals |
| subjects | Acids Age Antigens Apolipoproteins Biomarkers Biopsy Blood Cancer therapies Clotting Diagnosis Health aspects Life Sciences Mass spectrometry Mass spectroscopy Medical examination Medicare Older people Patients Peptides Peripheral blood Prostate cancer Prostate-specific antigen Proteins Proteomics Radiation therapy Scientific imaging Surveillance Tumors Urogenital system |
| title | A Novel Blood Proteomic Signature for Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A01%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Blood%20Proteomic%20Signature%20for%20Prostate%20Cancer&rft.jtitle=Cancers&rft.au=Muazzam,%20Ammara&rft.date=2023-02-07&rft.volume=15&rft.issue=4&rft.spage=1051&rft.pages=1051-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15041051&rft_dat=%3Cgale_pubme%3EA743010031%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2779531227&rft_id=info:pmid/36831393&rft_galeid=A743010031&rfr_iscdi=true |